Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia

Feb 24 2012

• By Alex Lash, John Davis, and Paul Bonanos

Related Content

Alzheimer’s Player Satori Wades Into Fray With Mystery Technology – And $22 Million

Jan 12 2009

Oncology Target Option Deal With GSK Helps Vernalis Hit Comeback Trail

Aug 06 2009

Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market

Feb 10 2012

Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product

Feb 22 2012

France's Adocia Completes 2012's First Euro Biotech IPO

Feb 15 2012

Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Jan 17 2011

From Friends To Foes: Tekmira Slaps Partner Alnylam With Lawsuit

Mar 17 2011

Related Companies

Gilead Sciences, Inc.

Alnylam Pharmaceuticals Inc.

Ligand Pharmaceuticals, Inc.

Adocia

EOS Imaging SA

Satori Pharmaceuticals, Inc.

Tris Pharma, Inc.

UCB S.A.

UCB S.A.

GSK plc

Exelixis, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window